Nutcracker Therapeutics
Sam Deutsch leads biological research and development at Nutcracker Therapeutics, as Senior Vice President, Research & Early Development. Sam orchestrates the development of Nutcracker’s therapeutics through close interactions between internal R&D, advisors and clinical collaborators. Prior to Nutcracker, Sam led the DNA synthesis platform at the Joint Genome Institute part of Lawrence Berkeley National Laboratory. Sam’s experience also includes research in molecular hematology at the Geneva University Hospital, and cancer genomics at the World Health Organization.
Sam was awarded a B.Sc. in Genetics from University of Nottingham and received his Ph.D. from the University of Geneva. Sam is the author of over 65 peer reviewed papers.
This person is not in any offices
Nutcracker Therapeutics
Nutcracker Therapeutics is an early-stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on the novel ACORN (Automation COntroled RNA) microfluidic-based manufacturing system.